TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16145319

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (0.05 mg 17[beta]-estradiol every 24 hours combined with 5 mg oral dydrogesterone daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (2 mg 17[beta]-estradiol semihydrate every 24 hours combined with 10 mg dydrogesterone)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral hormone therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hormone therapy (both routes)
Number of subjects: 90
Study: 12165639

Group type: EXPERIMENTAL
Intervention: Whole breast irradiation of 42.5 Gy in 16 fractions over 22 days (short arm)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Whole breast irradiation of 50 Gy in 25 fractions over 35 days (long arm)
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Short arm (22-day schedule)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Long arm (35-day schedule)
Number of subjects: 1234
Study: 10089978

Group type: EXPERIMENTAL
Intervention: Mast cell activity measured by tryptase levels in effusion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tryptase levels in effusion of atopic patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Presence of mast cells in middle ear biopsies
Number of subjects: 33

Group type: COMPARATOR
Intervention: Presence of mast cells in normal ears
Number of subjects: 33
Study: 7844665

Group type: EXPERIMENTAL
Intervention: Hib oligosaccharide conjugate (HbOC) at birth
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diphtheria and tetanus toxoids (DT) at birth
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (HbOC or PRP-tetanus toxoid conjugate (PRP-T) starting at 2 months)
Number of subjects: 150
Study: 2185461

Group type: EXPERIMENTAL
Intervention: Rocker bottom crutches
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional axillary crutches
Number of subjects: 150
Study: 681999

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 110
Study: 28631179

Group type: EXPERIMENTAL
Intervention: Volasertib alone
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Volasertib in combination with cytarabine
Number of subjects: 501

Group type: COMPARATOR
Intervention: Cytarabine alone
Number of subjects: 501

Group type: COMPARATOR
Intervention: Cytarabine in combination with volasertib
Number of subjects: 501
Study: 27632147

Group type: EXPERIMENTAL
Intervention: Regular mobile phone text reminders
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Regular mobile phone text reminders for newly initiated ART patients (<3 months)
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Regular mobile phone text reminders for urban newly initiated ART patients
Number of subjects: 830

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 830
Study: 25035291

Group type: EXPERIMENTAL
Intervention: Lomustine 110 mg/m² once every 6 weeks
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg once every 2 weeks
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg every 2 weeks and lomustine 90 mg/m² every 6 weeks
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg every 2 weeks and lomustine 110 mg/m² every 6 weeks
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Combined bevacizumab and lomustine groups
Number of subjects: 153

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 153

Group type: COMPARATOR
Intervention: Lomustine alone
Number of subjects: 153

Group type: COMPARATOR
Intervention: Bevacizumab and lomustine 90 mg/m²
Number of subjects: 153
Study: 22327087

Group type: EXPERIMENTAL
Intervention: 17-week half marathon training program (TP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20
Study: 19927018

Group type: EXPERIMENTAL
Intervention: LHTL
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 18752692

Group type: EXPERIMENTAL
Intervention: Food-based intervention consisting of six food items with modified cation content and 500 ml of maas (fermented milk)/d for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control diet providing the same quantities of targeted foods but of standard commercial composition and 500 ml/d of artificially sweetened cooldrink
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Food-based intervention
Number of subjects: 80
Study: 16248242

Group type: EXPERIMENTAL
Intervention: Acupoint stimulating control (ASC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Chlorimipramine (Control)
Number of subjects: 65
Study: 12969415

Group type: EXPERIMENTAL
Intervention: Emergency management condition (usual condition + emergency-management-focused teaching)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Usual condition (reading and discussion program)
Number of subjects: 219
Study: 11137328

Group type: EXPERIMENTAL
Intervention: Oral oestradiol (1 mg) combined with Chlormadinone Acetate 5 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 50 microg/24 h with Norethisterone Acetate (11.2 or 22.4 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 9186533

Group type: EXPERIMENTAL
Intervention: Conventional induction treatment with daunorubicin and cytarabine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 118

Group type: COMPARATOR
Intervention: Patients below 40 years of age
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Allogeneic vs Autologous bone marrow transplantation
Number of subjects: 118
Study: 8244812

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (20 Gy in a single fraction using 9-20 MeV electrons)
Number of subjects: 26

Group type: COMPARATOR
Intervention: External beam radiotherapy (daily 150-180 cGy fractions to 45-55 Gy in 5-6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intraoperative radiotherapy or external beam radiotherapy
Number of subjects: 26
Study: 3104051

Group type: EXPERIMENTAL
Intervention: Liquid antacid preparation 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid antacid preparation 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preference study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reasons for preference
Number of subjects: 0
Study: 31634188

Group type: EXPERIMENTAL
Intervention: Lateral flow assay (LFA) measuring tenofovir adherence
Number of subjects: 300

Group type: COMPARATOR
Intervention: LC-MS/MS (gold-standard method)
Number of subjects: 300
Study: 29358194

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment with higher HDL cholesterol levels at month 3
Number of subjects: 9542
Study: 26888227

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg for the first dose and then 200 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Loxoprofen (60 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Acetaminophen (600 mg)
Number of subjects: 160
Study: 24378207

Group type: EXPERIMENTAL
Intervention: DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vitamin D3 24,000-IU tablet (reference drug)
Number of subjects: 36
Study: 21553939

Group type: EXPERIMENTAL
Intervention: Self-initiated physical activity
Number of subjects: 106
Study: 20877353

Group type: COMPARATOR
Intervention: 5-FU
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: 5-FU+FA
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: 5-FU+IFNα
Number of subjects: 796
Study: 18794697

Group type: EXPERIMENTAL
Intervention: Rectal trumpet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fecal collector
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 16094218

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (high potency)
Number of subjects: 1559

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (any varicella potency)
Number of subjects: 1559

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (1 or 2 injections)
Number of subjects: 1559

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (second injection)
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Concomitant administration of M-M-RII and VARIVAX
Number of subjects: 1559

Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 1559
Study: 12571431

Group type: EXPERIMENTAL
Intervention: Nefazodone monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined treatment with amitriptyline and haloperidol
Number of subjects: 0
Study: 10561963

Group type: EXPERIMENTAL
Intervention: Terbinafine cream for 1 week
Number of subjects: 48

Group type: COMPARATOR
Intervention: Miconazole cream for 4 weeks
Number of subjects: 48
Study: 8678082

Group type: EXPERIMENTAL
Intervention: TMP-SMX 160/800 mg orally every 12 hours for 2 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 54
Study: 1283588

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Enalapril
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Verapamil or Enalapril
Number of subjects: 54
Study: 6584451

Group type: EXPERIMENTAL
Intervention: Hard toothbrush with bristle thickness of 0.23 mm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Soft toothbrush with bristle thickness of 0.15 mm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Abrasive dentifrice
Number of subjects: 24

Group type: COMPARATOR
Intervention: No dentifrice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderately abrasive toothpaste
Number of subjects: 24
Study: 30916886

Group type: EXPERIMENTAL
Intervention: Lateral tarsal strip with everting sutures (LTS + ES)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Quickert procedure (QP)
Number of subjects: 52
Study: 28217941

Group type: EXPERIMENTAL
Intervention: Mixed-mode survey methods (Internet-based and postal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postal-only survey methods
Number of subjects: 0
Study: 27418270

Group type: EXPERIMENTAL
Intervention: Adjuvant girentuximab treatment
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: BMI 30-34.9
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: BMI ≥35
Number of subjects: 845
Study: 23862586

Group type: COMPARATOR
Intervention: Two-layer microsurgical vasovasostomy (TLMVV)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Macroscopic one-layer vasovasostomy (MOLVV)
Number of subjects: 206
Study: 21555676

Group type: EXPERIMENTAL
Intervention: Lower BP goal defined by a mean arterial pressure goal of ≤92 mm Hg
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Usual BP goal defined by a mean arterial pressure goal of 102 to 107 mm Hg
Number of subjects: 1094
Study: 20143923

Group type: EXPERIMENTAL
Intervention: Lymphatic microsurgical procedures or tissue debulking with special staining techniques
Number of subjects: 0
Study: 16710287

Group type: EXPERIMENTAL
Intervention: Combination therapy of irbesartan (ARB) and ramipril (ACE inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramipril (ACE inhibitor) alone
Number of subjects: 0
Study: 15587588

Group type: EXPERIMENTAL
Intervention: Tyrothricin (0.1 g tyrothricin per 100 g of vehicle) applied twice daily for 9 days
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo powder applied twice daily for 9 days
Number of subjects: 131
Study: 11378187

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 9215784

Group type: EXPERIMENTAL
Intervention: Temporary 125I implants with a median reference dose of 60 Gy
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Permanent 125I implants with a median reference dose of 100 Gy
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Temporary implants
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: 200 Gy isodose volume <4.5 ml
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: 200 Gy isodose volume >4.5 ml
Number of subjects: 515
Study: 8485323

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) with high lipid content
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 18
Study: 3609119

Group type: EXPERIMENTAL
Intervention: 5-FU 7.5 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5-FU 15 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5-FU 7.5 mg/kg and 15 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 6
Study: 29080044

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo twice a day for 3 months
Number of subjects: 48
Study: 26515021

Group type: EXPERIMENTAL
Intervention: Exposure to a larger social network (8 speakers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to a smaller social network (2 speakers)
Number of subjects: 0
Study: 24047644

Group type: EXPERIMENTAL
Intervention: Six-month physical activity stimulation programme involving counselling through motivational interviewing, home-based physiotherapy and four months of fitness training.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Regular paediatric physiotherapy (Control group).
Number of subjects: 49
Study: 23307962

Group type: EXPERIMENTAL
Intervention: Flicker stimulation in diabetic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Laser Doppler velocimetry in diabetic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pattern electroretinography (ERG)
Number of subjects: 100
Study: 20621334

Group type: EXPERIMENTAL
Intervention: Relaxation response training (RR)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Arthritis education (AE)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavior therapy (CBT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: All treatment groups aggregated
Number of subjects: 168
Study: 18676087

Group type: EXPERIMENTAL
Intervention: 300 mg micronized progesterone for 21 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 20192924

Group type: EXPERIMENTAL
Intervention: Combined test performed at the 12th week of gestation
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Combined test
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Biochemical screening and ultrasonographic markers
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Combined test at 11-13+6 weeks' gestation
Number of subjects: 745
Study: 16361638

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 U/kg subcutaneously 3 times weekly until 3 weeks after completion of chemotherapy
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 224
Study: 12479890

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study: 9630831

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8160250

Group type: EXPERIMENTAL
Intervention: Oral fluphenazine dihydrochloride 5 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral fluphenazine dihydrochloride 10 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral fluphenazine dihydrochloride 20 mg
Number of subjects: 37
Study: 3292710

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 40 mg orally four times daily
Number of subjects: 138

Group type: COMPARATOR
Intervention: Tamoxifen 10 mg orally twice a day
Number of subjects: 138
Study: 11277161

Group type: EXPERIMENTAL
Intervention: AWHONN/NANN Neonatal Skin Care Research‐Based Clinical Practice Guideline
Number of subjects: 2820
Study: 29457998

Group type: EXPERIMENTAL
Intervention: PR plus quadricipital home‐based NMES (35Hz, 30min, 5 times per week)
Number of subjects: 73

Group type: COMPARATOR
Intervention: PR without NMES
Number of subjects: 73
Study: 26675768

Group type: EXPERIMENTAL
Intervention: Yellow cassava (mean content: 1460 μg β‐carotene/d)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: β‐carotene supplement (1053 μg/d)
Number of subjects: 342

Group type: COMPARATOR
Intervention: White cassava and placebo supplement (control group)
Number of subjects: 342
Study: 24813595

Group type: EXPERIMENTAL
Intervention: Cinnamon supplements (1.5 g/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22066961

Group type: EXPERIMENTAL
Intervention: AQUACEL(®) Ag
Number of subjects: 281

Group type: COMPARATOR
Intervention: Urgotul(®) Silver
Number of subjects: 281
Study: 20039146

Group type: EXPERIMENTAL
Intervention: Selenium levels in hemodialysis patients (HD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Selenium levels in continuous ambulatory peritoneal dialysis patients (CAPD)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Comparison of selenium levels between HD and CAPD patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Selenium levels in spent dialysate effluent fluid of CAPD patients
Number of subjects: 103
Study: 18812344

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) morphine sulfate interpleurally for 24 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.25% bupivacaine with epinephrine interpleurally for 24 hours
Number of subjects: 36
Study: 16047469

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg bd for 12 weeks (n = 6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo for 12 weeks (n = 7)
Number of subjects: 13
Study: 12496063

Group type: EXPERIMENTAL
Intervention: 160 mg/day of red clover-derived dietary isoflavones
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 38
Study: 10521110

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 422

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Age-related factors
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Cleavage status
Number of subjects: 422
Study: 7480524

Group type: EXPERIMENTAL
Intervention: ECTx3 (three times weekly electroconvulsive therapy)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined groups (ECTx2 and ECTx3)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ECT (any group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Post-treatment
Number of subjects: 47
Study: 2126420

Group type: EXPERIMENTAL
Intervention: 50 g MCT/LCT fats twice weekly
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.7 g/kg body weight per day MCT/LCT fats
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1.5 g/kg body weight per day MCT/LCT fats
Number of subjects: 3
Study: 760752

Group type: EXPERIMENTAL
Intervention: BW501 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BW501 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BW501 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methysergide 2 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 24
Study: 30449171

Group type: EXPERIMENTAL
Intervention: Personalized diet (1.2‐1.5 g/kg of protein, 30% of energy from fat, 55‐60% of energy from carbohydrate), face to face nutrition education, pamphlet with nutrition information
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Personalized diet, face to face nutrition education, pamphlet with nutrition information
Number of subjects: 150

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 150
Study: 30373993

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) in standing posture
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) in seated posture
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV)
Number of subjects: 20
Study: 28586607

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Symptomatic treatment for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment
Number of subjects: 100
Study: 24140659

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1108
Study: 22318197

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 38
Study: 20673892

Group type: EXPERIMENTAL
Intervention: Low-dose human chorionic gonadotropin (hCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estradiol/progesterone (E(2)/P)
Number of subjects: 0
Study: 17404369

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (2 cycles of carboplatin AUC 6 and paclitaxel 200 mg/m2 every 21 days) followed by concurrent chemoradiotherapy (66 Gy of chest radiotherapy with carboplatin AUC 2 and paclitaxel 50 mg/m2 weekly)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone (66 Gy of chest radiotherapy with carboplatin AUC 2 and paclitaxel 50 mg/m2 weekly)
Number of subjects: 366
Study: 15798610

Group type: EXPERIMENTAL
Intervention: Intravenous fibrinolysis (IVF) with urokinase 900,000 units
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intra-arterial fibrinolysis (IAF) with urokinase 900,000 units
Number of subjects: 27

Group type: COMPARATOR
Intervention: Primary outcome: modified Rankin score of 2 or less
Number of subjects: 27

Group type: COMPARATOR
Intervention: Secondary outcomes: mortality, frequency of symptomatic intracranial haemorrhage (SIH), neurological and functional scores
Number of subjects: 27
Study: 12030662

Group type: EXPERIMENTAL
Intervention: Follow-up assessment by the community mental health team (CMHT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Routine general practitioner (GP) care
Number of subjects: 93